Trial Profile
A retrospective study evaluating disruption of first-line treatment with palbociclib, among post-menopausal women with HR+/HER2- metastatic breast cancer (mBC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 11 May 2018 New trial record